Overview
Pierre Cervantes practices practicing medicine in Vantoux, France.
His clinical expertise encompasses Obesity Hypoventilation Syndrome (OHS) and Squamous Cell Lung Carcinoma.
He is actively involved in clinical research, co-authoring 3 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Pierre Cervantes
Is Pierre Cervantes a top-rated expert for Obesity Hypoventilation Syndrome (OHS)?
MediFind is an objective health platform that identifies experts based on real-world data. Pierre Cervantes is classified as an Experienced expert for Obesity Hypoventilation Syndrome (OHS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Pierre Cervantes participate in research or clinical trials?
Yes. Pierre Cervantes has published 3 articles and abstracts on conditions like Obesity Hypoventilation Syndrome (OHS). You can view a list of Pierre Cervantes's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Obesity Hypoventilation Syndrome (OHS)Mr. Cervantes isExperienced. Learn about Obesity Hypoventilation Syndrome (OHS).
- Squamous Cell Lung CarcinomaMr. Cervantes isExperienced. Learn about Squamous Cell Lung Carcinoma.